Sign up to save your podcasts
Or
Share Expanded Approvals for Durvalumab, Lu 177 vt; Portland Preview
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Expanded Approvals for Durvalumab, Lu 177 vt; Portland Preview
FDA expands approvals for durvalumab (bladder cancer) and Lutetium-177 vipivotide tetraxetan (pre-taxane in metastatic prostate cancer). Portland has places.
View all episodes
By John Bossaer
4.9
179179 ratings
FDA expands approvals for durvalumab (bladder cancer) and Lutetium-177 vipivotide tetraxetan (pre-taxane in metastatic prostate cancer). Portland has places.
More shows like OncoPharm
View all
JAMA Editors' Summary
128 Listeners
NEJM This Week
317 Listeners
JAMA Clinical Reviews
481 Listeners
The Curbsiders Internal Medicine Podcast
3,326 Listeners
Up First from NPR
56,158 Listeners
Core IM | Internal Medicine Podcast
1,094 Listeners
The ONS Podcast
197 Listeners
ASCO Guidelines
44 Listeners
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
695 Listeners
OncLive® On Air
21 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
320 Listeners
The Curious Clinicians
363 Listeners
WolverHeme Happy Hour
28 Listeners
Two Onc Docs
166 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
36 Listeners